相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
R. Lencioni et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani et al.
ANNALS OF ONCOLOGY (2013)
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
Takahide Nakazawa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma
Hwi Young Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
Ju-Yeon Cho et al.
LIVER INTERNATIONAL (2013)
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis
Joanne Chiu et al.
CANCER (2012)
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Taiga Otsuka et al.
HEPATOLOGY RESEARCH (2012)
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni et al.
JOURNAL OF HEPATOLOGY (2012)
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Jeong Eun Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2011)
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
Masatoshi Kudo et al.
EUROPEAN JOURNAL OF CANCER (2011)
Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy
Massimo Iavarone et al.
HEPATOLOGY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
Sadahisa Ogasawara et al.
HEPATOLOGY INTERNATIONAL (2011)
The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Thomas Yau et al.
ONCOLOGIST (2011)
Early Decrease in alpha-Fetoprotein, but Not Des-gamma-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2011)
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Matthias Pinter et al.
ONCOLOGIST (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
G D'Amico et al.
JOURNAL OF HEPATOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
分享论文
